Showing 41 - 60 results of 808 for search '"mutant"', query time: 0.06s Refine Results
  1. 41

    Lack of GAGA protein in Trl mutants causes massive cell death in Drosophila spermatogenesis and oogenesis by N. V. Dorogova, A. E. Zubkova, E. V. Fedorova, E. U. Bolobolova, E. M. Baricheva

    Published 2021-06-01
    “…Thus, GAF lack in Trl mutants leads to increased germ cell death through apoptosis and autophagy. …”
    Get full text
    Article
  2. 42

    A New gcrR-Deficient Streptococcus mutans Mutant for Replacement Therapy of Dental Caries by Wenting Pan, Tiantian Mao, Qing-an Xu, Jin Shao, Chang Liu, Mingwen Fan

    Published 2013-01-01
    “…S. mutans UA159 and the mutant MS-gcrR-def were inoculated, respectively, or together for competitive testing in vitro and in rat model. …”
    Get full text
    Article
  3. 43
  4. 44

    Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2 by Satoru Miyazaki, Masato Kitazawa, Satoshi Nakamura, Makoto Koyama, Yuta Yamamoto, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Michiko Takeoka, Daisuke Komatsu, Yuji Soejima

    Published 2025-02-01
    “…Accordingly, simultaneous inhibition of KRAS, MEK, and JAK2 could be an innovative therapeutic strategy against KRAS‐mutant pancreatic cancer.…”
    Get full text
    Article
  5. 45
  6. 46
  7. 47
  8. 48

    BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report by Yasar Subutay Peker, Mehmet Fatih Can, Ismail Hakki Ozerhan, Gokhan Yagci, Nazif Zeybek, Kutan Kavakli, Sedat Gurkok, Alper Gozubuyuk, Onur Genc, Gokhan Erdem, Ahmet Ozet, Mustafa Gerek, Yusuf Peker

    Published 2018-01-01
    “…BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. …”
    Get full text
    Article
  9. 49
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54

    Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermally by Marcela F. Pasetti, Patricia L. Milletich, Jessica A. White, Jessica Butts, Rebecca C. Brady, Michelle D. Dickey, Cassandra Ballou, Nicole Maier, Marcelo B. Sztein, Shahida Baqar, A. Louis Bourgeois, David I. Bernstein

    Published 2025-02-01
    “…A Phase 1, double-blind, dose-escalation (0.1-2.0 µg) study was conducted to evaluate the safety and immunogenicity of double mutant heat-labile toxin LTR192G/L211A (dmLT) delivered intradermally (ID) to healthy adults. …”
    Get full text
    Article
  15. 55

    Anthracyclines disaggregate and restore mutant p63 function: a potential therapeutic approach for AEC syndrome by Fabiana Boncimino, Ludovica D’Auria, Kristina Todorova, Sabina Y. van der Zanden, Jacques Neefjes, Anna Mandinova, Caterina Missero, Stefano Sol

    Published 2025-01-01
    “…Our findings identify compounds that can partially resolve mutant p63 aggregation, increase its monomeric isoform, and reactivate its transcriptional function. …”
    Get full text
    Article
  16. 56
  17. 57

    Derivation and Characterization of Isogenic <i>OPA1</i> Mutant and Control Human Pluripotent Stem Cell Lines by Katherine A. Pohl, Xiangmei Zhang, Johnny Jeonghyun Ji, Linsey Stiles, Alfredo A. Sadun, Xian-Jie Yang

    Published 2025-01-01
    “…In comparison to the isogenic controls, the heterozygous mutant PSCs expressed the same OPA1 protein isoforms but at reduced levels; whereas the homozygous mutant PSCs showed a loss of OPA1 protein and altered mitochondrial morphology. …”
    Get full text
    Article
  18. 58

    Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report by Hannah Haile, Pavan S. Upadhyayula, Esma Karlovich, Michael B. Sisti, Brian J. A. Gill, Laura E. Donovan

    Published 2025-01-01
    “…In this case report, we describe the management of a 67-year-old male with BRAFV600E -mutant GBM, who experienced both local clonal and distant non-clonal BRAFV600E -mutant recurrences. …”
    Get full text
    Article
  19. 59
  20. 60